FY2024 Earnings Estimate for Intelligent Bio Solutions Inc. Issued By Zacks Small Cap (NASDAQ:INBS)

Intelligent Bio Solutions Inc. (NASDAQ:INBS) – Equities researchers at Zacks Small Cap boosted their FY2024 earnings estimates for shares of Intelligent Bio Solutions in a research note issued to investors on Wednesday, November 15th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will post earnings per share of ($1.01) for the year, up from their previous forecast of ($4.56). The consensus estimate for Intelligent Bio Solutions’ current full-year earnings is ($3.44) per share. Zacks Small Cap also issued estimates for Intelligent Bio Solutions’ FY2025 earnings at ($0.47) EPS.

Intelligent Bio Solutions (NASDAQ:INBS) last issued its quarterly earnings results on Thursday, August 24th. The company reported ($1.91) EPS for the quarter, missing analysts’ consensus estimates of ($1.66) by ($0.25). The business had revenue of $0.44 million for the quarter, compared to the consensus estimate of $0.49 million. Intelligent Bio Solutions had a negative return on equity of 147.23% and a negative net margin of 510.29%.

Intelligent Bio Solutions Stock Performance

INBS opened at $0.52 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.25 and a current ratio of 0.39. The firm has a 50-day moving average of $0.65 and a 200 day moving average of $1.84. Intelligent Bio Solutions has a fifty-two week low of $0.20 and a fifty-two week high of $32.00.

Hedge Funds Weigh In On Intelligent Bio Solutions

A hedge fund recently bought a new stake in Intelligent Bio Solutions stock. Sabby Management LLC purchased a new stake in shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 126,650 shares of the company’s stock, valued at approximately $367,000. Intelligent Bio Solutions comprises about 0.3% of Sabby Management LLC’s holdings, making the stock its 26th largest holding. Sabby Management LLC owned 8.52% of Intelligent Bio Solutions at the end of the most recent reporting period. Institutional investors and hedge funds own 9.28% of the company’s stock.

Intelligent Bio Solutions Company Profile

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.